Videos

Brelovitug met the primary endpoint for virologic response and ALT normalization in the phase 2b portion of the AZURE-1 trial.

54-week STOP-HS safety data for the JAK1-selective inhibitor povorcitinib showed no dose-dependent safety signal and few laboratory abnormalities.

Study investigator Inusa explains the gap in sickle cell disease findings from SWAP, a multinational survey.

Isaacs covers the range of AID devices currently available and approved for T2D, providing suggestions for implementation and continuous glycated hemoglobin monitoring.

Study showed the PETRUSHKA decision-support tool reduced antidepressant discontinuation, supporting personalized treatment approaches.

The phase 3 trials enrolled frequent exacerbators regardless of eosinophil count or smoking status.

Phase 3 HAELO data show an 87% reduction in hereditary angioedema attack rates with a one-time CRISPR therapy. Banerji discusses efficacy, safety, and durability.

Viral Shah, MD, joins the show to break down his AACE 2026 presentation on the benefits of using GLP-1 RAs in patients with T1D.

Kass explains recent findings from a study that suggest myocardial dysfunction in HFpEF may be reversible with weight loss.

Kass explains 2 distinct biological subgroups discovered in HFpEF and how they relate to a paradigm shift.

Elizabeth Bauer, MD, joins the show to discuss her AACE 2026 presentation on key updates in obesity management and nutrition.

Auchus discusses the 2-year results from CAHtalyst Adult, highlighting the substantial retention rates over the open-label extension period.

Gill describes how storytelling and patient representation can build trust and education in Indigenous populations regarding transplantation.

Isaacs explains how prediabetes care is shifting toward early intervention, risk stratification, and prevention of cardiometabolic disease, not just progression to diabetes.

Hamidi reviews 2-year CAHtalyst data showing crinecerfont enabled sustained glucocorticoid reductions to physiologic range in adults with classic congenital adrenal hyperplasia.

Christopher Bunick, MD, PhD, and colleagues conducted a review bispecific and trispecific antibodies in atopic dermatitis.

Linda DiMeglio, MD, MPH, joins the show to discuss the growing movement towards screening and testing for T1D at an early stage.

Shah discusses the potential of GLP-1 receptor agonists as adjunctive therapy in type 1 diabetes, from glycemic control to cardiometabolic risk.

Mechanick discusses the importance of dietary interventions in endocrinology and highlights the need for further education and awareness of metabolic function.

In this segment of the interview, questions remaining about AI's effectiveness among patients in dermatology were explored.

Galindo describes how CKM may transform diabetes care by enabling real-time insights, improving DKA prevention, and advancing metabolic understanding.

Alva outlines how general clinicians should address patient questions on psychedelic therapies, including risks, approvals, and referral pathways.

Liu and Sayres emphasize that while AI tools improve consumer recognition of skin conditions, gaps remain in prediction accuracy and information.

Leventhal describes the limits of current immunosuppression and the rationale behind early-phase clinical trials evaluating cellular therapies.

In an interview, Bérard discusses cohort data showing no increased risk of major congenital malformations with ICS or ICS/LABA use in first trimester.

This interview highlights new data assessing whether artificial intelligence (AI)–powered tools can help consumers better understand dermatology cases.